By Inti Landauro
PARIS--French pharmaceutical giant Sanofi SA said Thursday that
it expects to launch 18 new drugs by 2020 that could boost sales by
up to EUR30 billion ($37.6 billion) over five years.
The company expects to launch six new drugs in 2015 and another
one every six months from 2016 to 2018. The string of new products
hitting the market is the result of an effort launched by the
company in 2008 to renovate its portfolio of products as many of
its best-selling drug patents were about to expire, said Chief
Executive Serge Weinberg, in a statement released ahead of a
presentation to investors.
The new drugs will treat rare diseases and diabetes as well as
providing improved care for cardiovascular ailments, immunology and
public health, said Elias Zerhouni, the company's head of research
and development.
The company also said Thursday that it expects revenue from
diabetes treatment sales to be flat to slightly higher between 2015
and 2018.
Separately it announced that the U.S. Food and Drug
Administration had agreed to speed up the approval process for
Dupilumab, a drug developed in partnership with Regeneron
Pharmaceutical Inc. to treat atopic dermatitis.
Write to Inti Landauro at inti.landauro@wsj.com
Access Investor Kit for Sanofi
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=FR0000120578
Access Investor Kit for Sanofi
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=US80105N1054
Subscribe to WSJ: http://online.wsj.com?mod=djnwires